Charles River Laboratories (CRL) Tops Q2 EPS by 40c; lowers guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $283.63 -1.69%
EPS Growth %: +21.8%
Financial Fact:
Income from continuing operations, net of tax: 37.69M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +21.8%
Financial Fact:
Income from continuing operations, net of tax: 37.69M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.80, $0.40 better than the analyst estimate of $2.40. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.02 billion.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $9.90-$10.20, versus the consensus of $10.99.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bessent: We Make A Market Buying Older Bonds
- Tarsus Pharmaceuticals (TARS) PT Raised to $105 at Jefferies
- Jefferies on MP Materials (MP): 'Magnet Ramp Remains on Track'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
